Should you buy Illumina stock now?
Yes, the technical signal for Illumina is currently BUY. Illumina trades at $189.15 as of 8/6/2026. The overall technical signal is: Strong Buy. The technical analysis shows the following: MACD is positive (bullish trend) at 6.566 with falling momentum (signal: 6.702); RSI is at 59.2 (neutral zone); the stock is in a short-term downtrend (price below the 20-day average); the analyst price target of $193.05 points to 2.1% upside. The stock is in a broader uptrend (above SMA50/SMA200). This is a technical observation based on current data, not investment advice.
What is the price target for Illumina stock?
The average analyst price target for Illumina is $193.05. The current price is $189.15, which gives an upside of 2.1%. Based on this, the stock is considered fairly valued. The fair value range (±10% of the price target) is between $173.75 and $212.36.
Is Illumina a dividend stock?
No, Illumina does not currently pay a dividend to shareholders. The company reinvests its profits in growth instead of paying dividends.
What is the risk of Illumina stock?
Illumina is rated as a stock with high risk. the annual standard deviation is 47.0%, which classifies the stock as high risk.
Is Illumina overvalued?
Illumina is considered fairly valued – the price is close to the analyst price target. Illumina has the following valuation ratios: a P/E ratio of 37.0 (highly valued), a P/S ratio of 6.8, a P/B ratio of 10.9. The stock trades close to the analyst price target and is considered fairly valued.
Is Illumina overbought?
No, Illumina is not overbought. RSI is at 59.2 (neutral zone). The technical indicators show: RSI is at 59.2 (neutral zone between 30-70), which signals neither overbought nor oversold. In addition, the price is 2.4% below the 20-day average (short-term downtrend). In addition, MACD is positive, but momentum is falling.
When is the next Illumina earnings report?
The date of the next earnings report for Illumina has not been published yet. Check the company's investor calendar for updates.
Is Illumina shorted?
Yes, Illumina is shorted with 9.5% of the free float sold short. This is a high level of short selling, which suggests some investors are betting on falling prices. Positive surprises can lead to a moderate short squeeze. Data is updated daily based on official filings with the SEC.
Are insiders buying Illumina stock?
No, insiders are not buying Illumina shares – they are net sellers. Over the last 3 months, insiders have made 10 purchases and 10 sales. On a net basis, 15,488,092 $ worth of shares were sold. Across the last 20 reported transactions, the split is 10 purchases and 10 sales, with a net 15,488,092 $ sold. Active sellers include Davies Scott M, Leckman Patricia, Meister Keith A. and others. Insider selling can have several explanations (e.g. planned 10b5-1 sales, portfolio diversification or taxes), but sustained selling by several insiders is worth watching closely.
Is Illumina a good stock?
Based on our total score, Illumina is rated as a good stock with a total score of 63 out of 100. The stock scores above average on value, quality and momentum – it is among the top 37% in our database. The score is made up of Value: 24/100, Quality: 68/100, Momentum: 97/100. In addition: technical signal: Strong Buy. Whether Illumina is a good investment depends on your time horizon, risk profile and portfolio. This is a data-driven observation, not investment advice.
What is the outlook for Illumina stock?
The outlook for Illumina based on current data: the average analyst price target is $193.05 (+2.1%); the stock is in an uptrend (above SMA50 and SMA200); the P/E ratio is 37.0 (high – the market expects growth). Keep in mind that stock prices are affected by many factors, including earnings reports, the economy and market sentiment. Past returns are no guarantee of future returns.
Why is Illumina stock falling?
Illumina is falling right now. The technical indicators show: the price is 2.4% below the 20-day average; short interest is 9.5% (high – many are betting on a decline); insiders have mostly been buying the stock recently. For the latest context, see our technical analysis, insider section and news overview above.
How high can Illumina go?
The average analyst price target for Illumina is $193.05, which corresponds to a potential gain of 2.1% from the current price of $189.15. Keep in mind that price targets are estimates, not guarantees. Actual price moves depend on earnings, market conditions and unexpected events.
How low can Illumina fall?
We lack enough history to give a specific floor for Illumina. Remember: past price swings are no guarantee for the future — a stock can fall further than the last 52 weeks suggest, especially on profit warnings, sector crises or a market crash. Use stop-loss orders and spread your portfolio to limit losses in single stocks.
What does Illumina do?
Illumina laver udstyr og løsninger til genetisk analyse. De er især kendt for deres sekventeringsmaskiner, som forskere og hospitaler bruger til at analysere DNA. Illumina tjener penge på at sælge både selve instrumenterne og de forbrugsstoffer, der skal bruges i analyserne.
... The company belongs to the Sundhed sector, more specifically the Diagnostics & Research industry, is headquartered in USA, and is traded on the USA Stocks. See the key figures, earnings history and price development above to evaluate Illumina as an investment.
Did Illumina raise or lower its guidance?
Over the last 60 days we have not registered a guidance raise or cut from Illumina. The company can still adjust its guidance at quarterly reports or between reports — see the earnings history and the news overview above.
Is Illumina making money or losing money?
Yes, Illumina is making money, not losing it. The company has a profit margin (the share of revenue left over as profit) of 18.3% — which is solid. The operating margin (profit before interest and taxes) is 21.1%. At a P/E ratio of 37.0, you currently pay 37.0 dollars for every dollar of the company's annual earnings. A consistently profitable company is usually more resilient than growth stocks that are not yet making money.
Can Illumina go bankrupt?
The bankruptcy risk of Illumina is rated as low. Altman Z2 (a model for assessing financial distress) is 3.10 — that places the company in the healthy zone. The company has a healthy balance sheet with limited debt relative to earnings and assets. The Piotroski score (financial health 0-9, higher is better) is 6 — which is average. Debt relative to equity is 166% (high). Remember: models like Altman Z2 are statistical — unexpected shocks (fraud, a sector collapse, lawsuits) can always happen. Spread your portfolio.
Does Illumina have a lot of debt?
Yes, Illumina has elevated debt relative to equity. The debt-to-equity ratio (D/E — interest-bearing debt to equity) is 166%. For the sundhed sector, anything above 150% counts as elevated — that raises the financial risk, especially if interest rates rise or earnings fall. Note: D/E levels are highly sector-specific — a bank at 300% debt is normal, a tech stock at 300% is extremely leveraged. Always compare with similar companies in the same sector.
